TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (NASDAQ:TGTX)

When I last wrote about TG Therapeutics ( TGTX ) in August, I noted a couple of softer quarters of Briumvi sales growth. I rated TGTX a hold at that time, as there was room for a TV campaign to aid sales nearer-term, withScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have a benef ...